Some positive news to anyone still holding ABMD.
http://investors.abiomed.com/news-releases/news-release-deta…
Eddie
4 Likes
You say that like no one should still be holding ABMD. This is a really great company with a recurring-replacement-revenue component that’s somewhat rare in the biomed space, and has done really well. And they’ve barely even tapped the global market. Not to mention the fact that they’re literally improving (and saving!) the lives of the patients whose doctors use Abiomed products.
Anyone who bought anywhere below the $300 mark has no good reason to be selling, IMO. ABMD is still one of my largest and highest-conviction holdings.
7 Likes
Anyone who bought anywhere below the $300 mark has no good reason to be selling, IMO. ABMD is still one of my largest and highest-conviction holdings.
I own a bit as well, but why anchor to the below $300 mark? If it’s a good company to own (and I agree that it is) it’s a good company to own, regardless of what you paid for it.
- just my $0.02; I’ll go back to lurking and learning.
2 Likes
Likewise one of my highest conviction holdings. (My basis does happen to be over the $300 mark; not concerned.)
It is on top of my targets to add, in the near future.
Besides all your normal financial research, there are some very useful anecdotal to the point comments regarding ABMD’s ‘product’, see postings from “HeartMD”, there are only a few board postings from a very busy cardio; quick reads, and more useful than most analysts’ insight. Worth bookmarking.
https://discussion.fool.com/sauls-investing-discussions-120980.a…
(Lots of other non-ABMD posts in the list; concentrate on the obvious ABMD subjects.)
Amazing what happens to the data when you take out the patients that got an RP who were already dead when they got it. Unbelievable some of the patients who got an RP in the post market study… SMH.
MC
4 Likes
Some goober posted a nothing rehash of known ABMD data on SeekingAlpha this morning, calling the FDA letter as a “risk.” It was so bad I’m not even going to link it from here. But hey, whatever gets those clicks in, right?
And to @gtechie – I wasn’t particularly tied to the $300 mark as much as maybe an EV/S or P/S metric as a gut check, which are a little kinder at that realm. Either way, you’re probably going to pay for good companies, and this is one of them. Wonderful human-facing charter, no debt, much room to expand, great product offerings and proven success…all on top of people not dying, with a recurring revenue stream. I just really do love owning this company and hope they hit multiple home runs as they enter new countries full bore.
3 Likes
Wonderful human-facing charter, no debt, much room to expand, great product offerings and proven success…all on top of people not dying, with a recurring revenue stream.
And don’t forget no real competition!
3 Likes